| 2023-11-29 | +457.8% | news | InvestorPlace | Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today? - InvestorPlace |
| 2023-11-29 | +457.8% | legal | Proactive Investors | Vivos Therapeutics stock soars as company receives first ever FDA 510(k) clearance for oral device treatment of sleep apnea - Proactive Investors |
| 2023-11-30 | -52.5% | legal | SEC EDGAR | VVOS 8-K: 8.01 (SEC Filing) |
| 2021-08-23 | +41.4% | legal | thestreet.com | Vivos Therapeutics Stock Leaps as FDA Clears Sleep-Apnea Device - thestreet.com |
| 2023-03-01 | -36.6% | M&A | Seeking Alpha | Vivos stock surges ~30% on acquiring dental product rights from Advanced Facialdontics - Seeking Alpha |
| 2026-04-16 | -35.2% | earnings | GuruFocus.com | Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... |
| 2024-03-29 | -30.1% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2024-09-19 | -26.6% | news | Seeking Alpha | Vivos Therapeutics announces $4.3M registered direct offering of common stock |
| 2025-05-16 | -25.3% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$0.45 misses by $0.10, revenue of $3.02M misses by $1.18M |
| 2025-07-01 | +20.8% | news | Stock Titan | Medicare Breakthrough: Revolutionary Sleep Apnea Treatment Now Covered for Millions of Americans - Stock Titan |
| 2025-07-01 | +20.8% | news | StocksToTrade | VVOS Stock Surge: What’s Driving This Boom? - StocksToTrade |
| 2026-04-15 | -20.3% | news | GlobeNewswire | Vivos Therapeutics Reports Full Year 2025 Financial Results |
| 2026-04-15 | -20.3% | news | GlobeNewswire | Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call |
| 2026-04-15 | -20.3% | earnings | Moby | Vivos Therapeutics, Inc. Q4 2025 Earnings Call Summary |
| 2026-04-15 | -20.3% | news | Seeking Alpha | Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential |
| 2026-04-15 | -20.3% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript |
| 2026-04-15 | -20.3% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$2.07 misses by $0.04, revenue of $17.44M misses by $3.27M |
| 2026-04-15 | -20.3% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2026-04-15 | -20.3% | news | Stock Titan | Vivos investors get 2025 results and strategy update at 5 p.m. ET - Stock Titan |
| 2026-04-15 | -20.3% | analyst | Stock Titan | Vivos grows on sleep apnea services, but operating loss hits $19.9M - Stock Titan |
| 2026-04-15 | -20.3% | earnings | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) grows 2025 revenue as net loss widens - Stock Titan |
| 2026-04-15 | -20.3% | M&A | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) details SCN deal and new sleep-center strategy - Stock Titan |
| 2022-06-15 | +19.8% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2026-04-14 | +18.5% | news | MSN | HC Wainwright & Co. Initiates Coverage of Vivos Therapeutics (VVOS) with Buy Recommendation - MSN |
| 2025-05-15 | -17.6% | M&A | Seeking Alpha | Vivos Therapeutics signals transformative growth with SCN acquisition and expects positive cash flow by end of 2025 |
| 2025-05-15 | -17.6% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript |
| 2025-05-15 | -17.6% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2025-05-15 | -17.6% | M&A | Stock Titan | Vivos Therapeutics Transforms Business Model with $9M Sleep Center Deal as Product Sales Rise - Stock Titan |
| 2021-11-15 | -17.5% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2024-06-14 | -17.2% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-01-22 | -17.2% | news | Seeking Alpha | Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders |
| 2025-02-14 | -17.0% | legal | SEC EDGAR | VVOS 8-K: 1.01, 5.02 (SEC Filing) |
| 2022-03-31 | -16.5% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2025-03-31 | -16.4% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$2.22 misses by $0.20, revenue of $15.03M misses by $0.17M |
| 2025-03-31 | -16.4% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +15.6% | M&A | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) delays 2025 Form 10-K, cites SCN acquisition - Stock Titan |
| 2021-08-12 | +15.5% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2024-07-10 | +15.1% | legal | SEC EDGAR | VVOS 8-K: 8.01 (SEC Filing) |
| 2024-02-06 | -13.6% | news | Stock Titan | Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities - Stock Titan |
| 2026-04-22 | -13.6% | news | Stock Titan | Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan |
| 2024-09-18 | +13.6% | legal | Seeking Alpha | Vivos surges on FDA nod for pediatric sleep apnea device |
| 2024-09-18 | +13.6% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2022-12-20 | -13.3% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2025-07-02 | +13.2% | news | simplywall.st | Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected - simplywall.st |
| 2025-11-19 | -13.0% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$0.49, revenue of $6.8M |
| 2025-11-19 | -13.0% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2024-11-15 | -12.3% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$0.40, revenue of $3.86M |
| 2024-11-15 | -12.3% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript |
| 2025-08-25 | +11.7% | legal | SEC EDGAR | VVOS 8-K: 2.01, 8.01 (SEC Filing) |
| 2023-02-09 | -11.4% | analyst | TradingView | VVOS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-07 | -11.0% | news | GlobeNewswire | Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners |
| 2026-04-07 | -11.0% | news | Stock Titan | Sleep-disorder company Vivos gets $2.25M from repeat investor - Stock Titan |
| 2025-04-01 | -10.7% | earnings | Seeking Alpha | Vivos therapeutics outlines expansion of sleep center alliances with $4,500 revenue per patient potential |
| 2025-04-01 | -10.7% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript |
| 2026-01-20 | -10.7% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02 (SEC Filing) |
| 2026-01-20 | -10.7% | M&A | Stock Titan | Sleep apnea device maker Vivos raises $4.64M in repriced warrant deal - Stock Titan |
| 2024-04-09 | -10.7% | news | Seeking Alpha | Medicare to reimburse for Vivos CARE sleep apnea devices |
| 2025-10-24 | -10.4% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2024-05-15 | -10.3% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$1.63, revenue of $3.4M |
| 2024-05-15 | -10.3% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2026-02-06 | +10.3% | legal | SEC EDGAR | VVOS 8-K: 5.02 (SEC Filing) |
| 2025-05-28 | +9.9% | news | Intellectia AI | VVOS Forecast — Price Prediction for 2026. Should I Buy VVOS? - Intellectia AI |
| 2021-10-22 | -9.8% | earnings | Zacks Investment Research | What date does Vivos Therapeutics's (VVOS) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-04-08 | -9.6% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Vivos Therapeutics (VVOS) Stock a Market Leader | Price at $1.23, Down 1.21% - Stock Trading Network - Cổng thông tin điện tử tỉnh Lào Cai |
| 2024-09-20 | -8.8% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-05-06 | -8.7% | legal | SEC EDGAR | VVOS 8-K: 8.01 (SEC Filing) |
| 2022-05-16 | +8.4% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2025-08-20 | +8.4% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$0.55, revenue of $3.82M |
| 2025-08-20 | +8.4% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2022-03-01 | +8.4% | legal | SEC EDGAR | VVOS 8-K: 5.02 (SEC Filing) |
| 2026-04-17 | -8.3% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16 - Popular Trader Picks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-04-17 | +8.0% | legal | SEC EDGAR | VVOS 8-K: 1.01 and (SEC Filing) |
| 2025-09-12 | -7.6% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2025-05-23 | +7.2% | legal | SEC EDGAR | VVOS 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2026-01-05 | -7.2% | analyst | Yahoo Finance | Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance |
| 2024-11-14 | -7.1% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | -6.6% | legal | MT Newswires | Vivos Therapeutics Insider Bought Shares Worth $1,813,858, According to a Recent SEC Filing |
| 2026-04-06 | -6.6% | news | Sahm | Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday - Sahm |
| 2025-11-20 | -6.2% | earnings | Seeking Alpha | Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans |
| 2025-11-20 | -6.2% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript |
| 2026-02-03 | -6.1% | news | Benzinga | Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Certara (NASDAQ:CERT), Vivo - Benzinga |
| 2024-02-27 | +5.9% | earnings | TradingView | Vivos Therapeutics, Inc. Earnings and Revenue – NASDAQ:VVOS - TradingView |
| 2026-01-16 | -5.8% | news | Seeking Alpha | Vivos Therapeutics announces exercise of warrants for $4.64M gross proceeds |
| 2026-01-16 | -5.8% | legal | SEC EDGAR | VVOS 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2026-01-16 | -5.8% | legal | Stock Titan | Sleep apnea device maker Vivos secures $4.64M from warrant exercise - Stock Titan |
| 2025-02-11 | -5.8% | news | Seeking Alpha | Vivos Therapeutics announces up to $50M mixed shelf offering |
| 2024-12-23 | -5.1% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-12-23 | -5.1% | legal | Stock Titan | Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - Stock Titan |
| 2026-03-28 | -4.9% | news | ACCESS Newswire | New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX) |
| 2025-06-13 | +4.9% | legal | SEC EDGAR | VVOS 8-K: 1.01, 2.03, 3.02, 8.01 (SEC Filing) |
| 2026-03-26 | +4.3% | news | Stock Titan | More Las Vegas sleep apnea patients gain coverage as Vivos cuts costs - Stock Titan |
| 2024-09-12 | -4.3% | legal | SEC EDGAR | VVOS 8-K: 5.02 (SEC Filing) |
| 2026-04-10 | +4.3% | news | Stock Titan | Vivos Therapeutics (VVOS) 10% holder reports large stock and warrant stakes - Stock Titan |
| 2023-03-02 | -4.2% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2022-11-22 | +4.0% | legal | SEC EDGAR | VVOS 8-K: 2.02, 4.02 (SEC Filing) |
| 2026-04-18 | +3.9% | news | ACCESS Newswire | New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS) |
| 2023-05-09 | +3.9% | legal | SEC EDGAR | VVOS 8-K: 4.01, 8.01 (SEC Filing) |
| 2024-02-15 | +3.8% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02 (SEC Filing) |
| 2024-08-15 | -3.6% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript |
| 2024-08-15 | -3.6% | earnings | Seeking Alpha | Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M |
| 2024-08-15 | -3.6% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2021-05-12 | -3.4% | legal | SEC EDGAR | VVOS 8-K: 1.01 and (SEC Filing) |
| 2022-10-18 | -3.1% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Vivos Therapeutics (VVOS) - Zacks Investment Research |
| 2025-09-18 | -3.0% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2026-02-05 | +2.7% | news | Stock Titan | Sound-based allergy and sleep bands join Vivos dentist network - Stock Titan |
| 2024-05-18 | -2.3% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript |
| 2025-12-16 | -2.1% | news | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript |
| 2025-12-16 | -2.1% | news | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) expands with MISleep-linked Detroit sleep center - Stock Titan |
| 2024-06-27 | +2.1% | news | Seeking Alpha | Vivos gains as pilot program validates new market model |
| 2025-04-16 | -2.0% | M&A | Seeking Alpha | Vivos Therapeutics to acquire operating assets of The Sleep Center of Nevada |
| 2025-12-15 | -2.0% | executive | Quiver Quantitative | Vivos Therapeutics, Inc. CEO and CFO Set to Discuss Strategic Business Model and Market Opportunities in Upcoming Fireside Chat | VVOS Stock News - Quiver Quantitative |
| 2022-07-18 | -1.9% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2021-09-27 | -1.7% | legal | SEC EDGAR | VVOS 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-02-13 | +1.7% | news | Stock Titan | VVOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan |
| 2023-11-02 | -1.7% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-12-17 | -1.6% | legal | SEC EDGAR | VVOS 8-K: 8.01 and (SEC Filing) |
| 2025-04-24 | +1.5% | news | Stock Titan | VVOS Stock Price, News & Analysis - Stock Titan |
| 2021-05-17 | -1.4% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2023-03-30 | +1.3% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2023-01-09 | -1.3% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-04-04 | -1.2% | news | The Globe and Mail | Vivos Therapeutics Completes Private Placement to Bolster Liquidity - The Globe and Mail |
| 2026-04-04 | -1.2% | earnings | Intellectia AI | VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI |
| 2026-04-03 | -1.2% | legal | SEC EDGAR | VVOS 8-K: 1.01, 3.02 (SEC Filing) |
| 2026-04-03 | -1.2% | news | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) gets $850,000 PIPE cash plus $1,400,000 bridge note conversion - Stock Titan |
| 2021-06-05 | -1.1% | news | ChartMill | VVOS Cash Flow | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill |
| 2023-06-08 | +0.9% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2024-06-25 | +0.9% | legal | SEC EDGAR | VVOS 8-K: 8.01 (SEC Filing) |
| 2025-11-04 | -0.8% | analyst | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript |
| 2023-08-16 | -0.7% | legal | SEC EDGAR | VVOS 8-K: 2.02 and (SEC Filing) |
| 2025-12-05 | +0.6% | legal | SEC EDGAR | VVOS 8-K: 1.01, 2.03 (SEC Filing) |
| 2025-08-22 | -0.5% | earnings | Seeking Alpha | Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript |
| 2026-04-02 | +0.2% | news | Investing.com | Vivos Therapeutics investor V-Co investors 3 LLC buys shares worth $1.8m By Investing.com - Investing.com |
| 2026-04-02 | +0.2% | news | Stock Titan | Vivos Therapeutics (NASDAQ: VVOS) investor buys stock, pre-funded warrants - Stock Titan |
| 2026-04-02 | +0.2% | news | Stock Titan | Investor group (NASDAQ: VVOS) funds Vivos with $2.39M PIPE and warrants - Stock Titan |
| 2026-04-11 | -0.2% | news | ACCESS Newswire | New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST) |
| 2026-04-11 | -0.2% | news | ACCESS Newswire | New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX) |